---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Topical therapies"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Topical therapies. Topics: Topical corticosteroids: guideline recommendation, potency selection, and efficacy ranges by potency class; Topical corticosteroids: local adverse effects, tachyphylaxis, and duration limits; Topical vitamin D analogues and corticosteroid combinations: guideline recommendations and adverse effects; Topical agents added to systemic therapy in moderate to severe psoriasis: guideline recommendations; 3 further topics. 7 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/topical-therapies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Topical therapies

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Topical Therapies

<a id="topic-2.2.2.1.1-1"></a>

### Topical corticosteroids: guideline recommendation, potency selection, and efficacy ranges by potency class

> “The use of class 1, class 2, and class 3-5 topical corticosteroids for up to 4 weeks is recommended for the treatment of plaque psoriasis not involving intertriginous areas”
> “In adults, corticosteroids in classes 2 through 5 (moderate to high potency; Table II) are generally recommended as initial therapy.”
> “For ultrahigh-potency (class 1) corticosteroids, the efficacy rates in several RCTs vary from 58% to 92%.”
> “For high-potency (class 2 and 3) corticosteroids, the efficacy rates in several RCTs vary from 68% to 74%.”
> “For moderate-potency (class 4 and 5) corticosteroids, the efficacy rates in several RCTs vary from 70% to 83%.”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="topic-2.2.2.1.1-2"></a>

### Topical corticosteroids: local adverse effects, tachyphylaxis, and duration limits

> “The most common local skin adverse effects of topical corticosteroid use include skin atrophy, striae, folliculitis, telangiectasia, and purpura.”
> “Tachyphylaxis may compromise the effectiveness in certain patients when used for an extended period >12 weeks.”
> “Clinicians should consider limiting the use of class 1 corticosteroids to no more than twice daily for up to 4 weeks, when possible”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="topic-2.2.2.1.1-3"></a>

### Topical vitamin D analogues and corticosteroid combinations: guideline recommendations and adverse effects

> “The long-term use of topical vitamin D analogues (up to 52 weeks), including calcipotriene/calcipotriene, calcitriol, tacalcitol, and maxacalcitol, is recommended for the treatment of mild to moderate psoriasis”
> “Use of combination products with calcipotriol and corticosteroids is recommended for the treatment of psoriasis”
> “Other local adverse effects can affect up to 35% of patients and include burning, pruritus, edema, peeling, dryness, and erythema.”
> “When using calcipotriene, applications of more than 100 g/wk should be avoided to minimize this risk”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="topic-2.2.2.1.1-4"></a>

### Topical agents added to systemic therapy in moderate to severe psoriasis: guideline recommendations

> “The addition of topical calcipotriene to standard dose methotrexate therapy is recommended for the treatment of moderate to severe psoriasis. It may lead to lower cumulative doses of methotrexate and increased time to relapse after methotrexate discontinuation”
> “The addition of calcipotriene/betamethasone to standard dose adalimumab for 16 weeks is recommended for the treatment of moderate to severe psoriasis to accelerate clearance of psoriatic plaques.”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="topic-2.2.2.1.1-5"></a>

### Topical agents alone among treated patients with moderate or severe psoriasis

> “Among those receiving treatment, 29.5% of patients with moderate psoriasis and 21.5% of patients with severe psoriasis were treated with topical agents alone.”

Source: [Armstrong et al. (2013d)](https://pubmed.ncbi.nlm.nih.gov/23945732/)

<a id="topic-2.2.2.1.1-6"></a>

### Guideline evidence base for topical and UV therapy statements

> “The statements on topical and UV therapies are based on the systematic evidence synthesis last updated in 2015.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.1-7"></a>

### Joint AAD-NPF guideline on topical therapy: scope and National Psoriasis Foundation collaboration

> “This guideline will cover the use of topical agents and alternative medicine (AM) in the treatment of psoriasis in adults as well as the assessment of disease severity”
> “This concludes the portion of the AAD-NPF Joint Guideline on care for the management of psoriasis with topical therapy.”
> “Additionally, this guideline is developed in collaboration with the National Psoriasis Foundation (NPF) and as part of the review process; the NPF medical board members provided their feedback.”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
